Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

InspireMD, Inc. NSPR

Healthcare  —  Medical Devices
0.70 0.00 0.00% as of 25 Sep
Market cap
$32.5M
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

InspireMD, Inc. (NSPR) Business Profile

Updated before January 2025

Company Overview

InspireMD, Inc. (NASDAQ: NSPR) is a medical device company dedicated to the development and commercialization of innovative technologies aimed at addressing unmet needs in the cardiovascular and neurovascular markets. Founded in 2005 and headquartered in Tel Aviv, Israel, InspireMD focuses on improving patient outcomes through its proprietary MicroNet™ technology. This technology is designed to enhance the safety and efficacy of stenting procedures, particularly in high-risk patients.

The company is led by an experienced management team. Marvin Slosman serves as the President and Chief Executive Officer, bringing extensive experience in the medical device and healthcare industries. Other key members of the leadership team include Craig Shore, the Chief Financial Officer, and Dr. Michael Berman, the Chairman of the Board, who has a strong background in medical innovation and entrepreneurship.

Core Business Segments

MicroNet™ Technology

At the core of InspireMD’s product portfolio is its proprietary MicroNet™ technology. This ultra-thin mesh is designed to be integrated with stents to prevent embolization, a common complication in stenting procedures. The technology is particularly effective in treating patients with complex vascular conditions, such as carotid artery disease and coronary artery disease.

CGuard™ Embolic Prevention System (EPS)

The CGuard™ EPS is InspireMD’s flagship product. It is a carotid stent system that incorporates the MicroNet™ technology to prevent embolic events during and after stenting procedures. The system is designed to improve patient outcomes by reducing the risk of stroke, a major concern in carotid artery disease treatment.

MGuard™ Prime Embolic Protection System

The MGuard™ Prime is another key product in InspireMD’s portfolio. It is a coronary stent system that utilizes the MicroNet™ technology to provide embolic protection during percutaneous coronary interventions (PCI). This product is particularly beneficial for patients with acute coronary syndromes, such as ST-elevation myocardial infarction (STEMI).

Neurovascular Applications

InspireMD is also exploring the application of its MicroNet™ technology in the neurovascular field. This includes the development of stent systems for the treatment of conditions such as ischemic stroke and intracranial atherosclerosis.

Business Model

InspireMD operates on a business model that combines innovation, strategic partnerships, and a focus on high-growth markets. The company generates revenue primarily through the sale of its stent systems, which are distributed globally through a network of distributors and direct sales channels. InspireMD also invests heavily in research and development to expand its product portfolio and maintain a competitive edge.

The company’s approach to integrating its products and services is centered on addressing unmet medical needs. By focusing on high-risk patient populations and leveraging its proprietary MicroNet™ technology, InspireMD aims to deliver superior clinical outcomes and drive adoption among healthcare providers.

Strategic Direction

InspireMD has outlined a clear strategic direction aimed at driving growth and expanding its market presence. Key elements of this strategy include:

  • Geographic Expansion: InspireMD is focused on expanding its footprint in key markets, including the United States, Europe, and Asia. The company is actively pursuing regulatory approvals and partnerships to facilitate market entry.
  • Product Innovation: InspireMD continues to invest in research and development to enhance its existing products and develop new applications for its MicroNet™ technology. This includes exploring opportunities in the neurovascular field.
  • Sustainability Goals: The company is committed to sustainability and aims to minimize its environmental impact through responsible manufacturing practices and supply chain management.
  • Clinical Evidence: InspireMD is conducting clinical trials to generate robust evidence supporting the safety and efficacy of its products. This is critical for driving adoption and securing reimbursement from healthcare payers.

Competitive Landscape

InspireMD operates in a highly competitive medical device market. Key competitors include:

  • Boston Scientific Corporation: A global leader in medical devices, offering a wide range of stent systems and embolic protection devices.
  • Medtronic plc: Another major player in the cardiovascular and neurovascular markets, known for its innovative stent technologies.
  • Abbott Laboratories: A leading provider of vascular devices, including stents and embolic protection systems.
  • Terumo Corporation: A Japanese medical device company with a strong presence in the cardiovascular market.

Despite the competition, InspireMD differentiates itself through its proprietary MicroNet™ technology, which offers unique benefits in embolic protection.

Risk Factors

InspireMD faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Market Dependence: The company’s revenue is heavily dependent on the success of its stent systems. Any decline in demand or adverse clinical outcomes could negatively affect its financial performance.
  • Regulatory Challenges: Obtaining and maintaining regulatory approvals is a significant challenge in the medical device industry. Delays or failures in securing approvals could hinder market entry.
  • Supply Chain Disruptions: InspireMD relies on a global supply chain for the production and distribution of its products. Disruptions in the supply chain could impact product availability and revenue.
  • Competition: The medical device market is highly competitive, with several established players. InspireMD must continuously innovate to maintain its competitive edge.

Recent Developments

In recent years, InspireMD has made significant strides in advancing its product portfolio and expanding its market presence. Key developments include:

  • Regulatory Approvals: InspireMD has secured regulatory approvals for its CGuard™ EPS in multiple markets, including Europe and Asia. The company is also pursuing FDA approval in the United States.
  • Clinical Trials: InspireMD has initiated several clinical trials to generate evidence supporting the safety and efficacy of its products. These trials are critical for driving adoption and securing reimbursement.
  • Partnerships: The company has entered into strategic partnerships with distributors and healthcare providers to expand its market reach.
  • Product Launches: InspireMD has launched new iterations of its stent systems, incorporating advanced features to enhance performance and ease of use.

Investment Considerations

Strengths

  • Innovative Technology: InspireMD’s proprietary MicroNet™ technology offers unique benefits in embolic protection, setting it apart from competitors.
  • Growing Market: The cardiovascular and neurovascular markets are expected to grow significantly, providing ample opportunities for InspireMD.
  • Experienced Leadership: The company is led by a seasoned management team with a strong track record in the medical device industry.

Risks

  • Regulatory Hurdles: Delays or failures in securing regulatory approvals could impact market entry and revenue growth.
  • Market Competition: InspireMD faces intense competition from established players in the medical device market.
  • Financial Performance: The company has yet to achieve consistent profitability, which could be a concern for investors.

Conclusion

InspireMD, Inc. is a promising player in the medical device industry, with a strong focus on innovation and addressing unmet medical needs. The company’s proprietary MicroNet™ technology and flagship products, such as the CGuard™ EPS, position it well for growth in the cardiovascular and neurovascular markets. While InspireMD faces challenges such as regulatory hurdles and market competition, its strategic direction and commitment to innovation provide a solid foundation for future success. Investors should weigh the company’s strengths and risks carefully when considering it as a potential investment opportunity.